VC dollars driving nanotech drug development for cancer

09/12/2007 | Wall Street Journal (free content), The

Investors increasingly are funding nanotechnology-based anti-cancer drugs under development by companies including BIND Biosciences, Tempo Pharmaceuticals and Avidimer Therapeutics. Venture capital firms are also looking at promising applications of nanotechnology in RNA-interference chemistries, such as those being developed by Interdigm Corp., and improved diagnosis, including work by Kereos.

View Full Article in:

Wall Street Journal (free content), The

Published in Brief:

SmartBrief Job Listings for Health Care